Short Interest in Iterum Therapeutics plc (NASDAQ:NRBO) Decreases By 64.0%

Iterum Therapeutics plc (NASDAQ:NRBO) was the recipient of a large decrease in short interest in the month of March. As of March 13th, there was short interest totalling 10,300 shares, a decrease of 64.0% from the February 27th total of 28,600 shares. Based on an average daily volume of 16,900 shares, the short-interest ratio is presently 0.6 days. Approximately 0.2% of the shares of the company are sold short.

An institutional investor recently bought a new position in Iterum Therapeutics stock. Hayden Royal LLC purchased a new position in shares of Iterum Therapeutics plc (NASDAQ:NRBO) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 34,176 shares of the company’s stock, valued at approximately $645,000. Hayden Royal LLC owned approximately 5.74% of Iterum Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 13.66% of the company’s stock.

NRBO has been the subject of several recent analyst reports. LADENBURG THALM/SH SH initiated coverage on shares of Iterum Therapeutics in a research note on Tuesday, February 18th. They issued a “buy” rating for the company. ValuEngine upgraded shares of Iterum Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd.

Shares of NASDAQ NRBO traded up $2.51 during midday trading on Thursday, reaching $14.16. 8,400 shares of the stock were exchanged, compared to its average volume of 28,053. The company has a market cap of $6.53 million, a PE ratio of -0.49 and a beta of 1.07. Iterum Therapeutics has a 52-week low of $5.95 and a 52-week high of $36.22.

Iterum Therapeutics Company Profile

NeuroBo Pharmaceuticals, Inc provides novel therapies for diabetic neuropathic pain and central nervous system diseases. NeuroBo Pharmaceuticals, Inc was founded in 2017 and is based in Boston, Massachusetts.

Featured Article: What is the Federal Reserve?

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with's FREE daily email newsletter.